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ABSTRACT OF PROPOSAL 
 
Adherence Measurement and Incidence of Bleeding and Systemic Embolism with 
Dabigatran in a Medicaid Population 
 
Investigators: Nicole Trask, Pharm.D., Payal N. Kotadiya, Pharm.D., BCPS, James Gagnon, 
Pharm.D., BCPS, Mark Kohn, Pharm.D., BCPS, Pavel Lavitas, Pharm.D., BCPS, Karen Lee, 
Pharm.D., BCPS,*, Andrea Lewtas, Pharm.D., Maria M. Lowe, Pharm.D., Alkiviadis 
Nacopoulos, Pharm.D., BCPS, Tamara Rosenzweig, Pharm.D., BCPS, Caroline Alper, MD, 
Paul Jeffrey, Pharm.D †.  
University of Massachusetts Medical School - Clinical Pharmacy Services 
333 South St. 
Shrewsbury, MA 01545 
 
Lead Investigator Contact Information: nicole.trask@umassmed.edu, 774.455.3262 
 
BACKGROUND: The use of warfarin for the treatment of atrial fibrillation (AF) is often 
complicated by the associated narrow therapeutic index and frequent monitoring. Dabigatran, 
an oral direct thrombin inhibitor, does not require routine monitoring, produces rapid therapeutic 
anticoagulation, and has the potential to improve thromboprophylaxis through increased 
adherence. As such, it is important to evaluate adherence and the incidence of bleeding and 
systemic embolism with dabigatran in a real-world population with AF.  
 
OBJECTIVE: To measure adherence and incidence of bleeding and systemic embolism with 
dabigatran in a state Medicaid population with AF. 
 
METHODS: Medicaid members >18 years of age with AF were included if they had >1 paid 
claim for dabigatran between February 1, 2011 and September 30, 2011. Members were 
excluded if they had breaks in Medicaid coverage, supplemental insurance or were a female of 
childbearing age. The index date was defined as the date of the first pharmacy claim for 
dabigatran. Adherence was measured using medication possession ratios (MPR) for members 
with >2 paid claims for dabigatran and members with an MPR >0.8 were considered adherent. 
The incidences of bleeding, stroke and all-cause hospitalization were determined using medical 
claims data for one year post-index date. Pharmacy claims data was used to report changes in 
anticoagulant therapy within one year post-index date. 
 
RESULTS: The average MPR was 0.87 and 69% of members were considered adherent. Of 
the members that started dabigatran, 42.9% continued dabigatran while 21.4% switched to 
warfarin. Overall, 16.7% of members experienced a systemic embolism and only one bleeding 
event occurred during the study period. While chest pain and dyspepsia were the most common 
adverse events, 45.2% of members had no adverse events.  
 
CONCLUSIONS: This evaluation found that while members were adherent to dabigatran 
therapy, the discontinuation rate suggests poor tolerance to therapy.  
